Taysha Gene Therapies (NASDAQ: TSHA) reported Q1 EPS of ($0.28), $0.08 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $4.71 million versus the consensus estimate of $0 .

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.